{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T13:35:42Z","timestamp":1793367342989,"version":"4.5.0"},"reference-count":68,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2004,11,18]],"date-time":"2004-11-18T00:00:00Z","timestamp":1100736000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Experimental Dermatology"],"published-print":{"date-parts":[[2004,12]]},"abstract":"<jats:p><jats:bold>Abstract:\u2002<\/jats:bold> Pimecrolimus is the most recent member of calcineurin inhibitors available for the therapy for inflammatory skin diseases. It targets T\u2010cells and mast cells and inhibits the production and release of cytokines and other inflammatory mediators, as well as the expression of signals essential for the activation of inflammatory T\u2010lymphocytes. Pimecrolimus has a cell\u2010selective mode of action. In contrast to corticosteroids, it does not affect, e.g., Langerhans'cells\/dendritic cells (LC\/DC), as demonstrated <jats:italic>in vitro<\/jats:italic> with human monocyte\u2010derived DC and <jats:italic>in vivo<\/jats:italic> with epidermal LC in mice, nor human primary fibroblasts. As shown <jats:italic>in vitro<\/jats:italic> with human skin and by comparison of clinical pharmacokinetic data from patients with atopic dermatitis, pimecrolimus permeates less through skin than tacrolimus and much less than corticosteroids. It, thus, has a lower potential for transcutaneous resorption after topical administration, resulting in a lower risk of systemic effects. Pimecrolimus has high anti\u2010inflammatory activity in animal models of skin inflammation, including a model reflecting neurogenic inflammation, but a more favourable balance of anti\u2010inflammatory vs. immunosuppressive activity than tacrolimus. Pimecrolimus does not affect sensitization in a murine model of allergic contact dermatitis and has a lower potency in various models of immunosuppression after systemic administration, compared to tacrolimus. In conclusion, the results of preclinical studies show that pimecrolimus has a selective pharmacological profile, suited for effective and safe treatment for inflammatory skin diseases.<\/jats:p>","DOI":"10.1111\/j.0906-6705.2004.00269.x","type":"journal-article","created":{"date-parts":[[2004,11,18]],"date-time":"2004-11-18T13:34:54Z","timestamp":1100784894000},"page":"721-730","source":"Crossref","is-referenced-by-count":102,"title":["Pimecrolimus \u2013 an anti\u2010inflammatory drug targeting the skin"],"prefix":"10.1111","volume":"13","author":[{"given":"M.","family":"Grassberger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Steinhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. A.","family":"Luger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2004,11,18]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(89)70339-X"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2002.121832"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2002.121831"},{"key":"e_1_2_8_5_2","first-page":"191","article-title":"Tacrolimus ointment for the treatment of atopic dermatitis: clinical and pharmacological effects","volume":"23","author":"Rico M","year":"2002","journal-title":"Allergy Asthma Proc"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(87)92829-7"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.128.6.781"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.132.4.419"},{"key":"e_1_2_8_9_2","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s00105-003-0519-0","article-title":"Entstehungsgeschichte und pr\u00e4klinisches Profil von Pimecrolimus","volume":"54","author":"Stuetz A","year":"2003","journal-title":"Hautarzt"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200262050-00007"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2003.1492"},{"key":"e_1_2_8_12_2","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/j.1742-1241.2003.tb10492.x","article-title":"Pimecrolimus: a review of preclinical and clinical data","volume":"57","author":"Graham\u2010Brown R A C","year":"2003","journal-title":"Int J Clin Pract"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.2002.00694.x"},{"issue":"1","key":"e_1_2_8_14_2","first-page":"391","article-title":"Treatment with oral pimecrolimus significantly improves psoriasis with a clear dose\u2010response effect","volume":"121","author":"Griffiths C","year":"2003","journal-title":"J Invest Dermatol"},{"issue":"1","key":"e_1_2_8_15_2","first-page":"1240","article-title":"Treatment with oral pimecrolimus significantly improves atopic dermatitis (AD) with a clear dose\u2010response effect","volume":"121","author":"Hanifin J","year":"2003","journal-title":"J Invest Dermatol"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1999.02974.x"},{"issue":"1","key":"e_1_2_8_17_2","first-page":"1225","article-title":"Effect of pimecrolimus, tacrolimus, cyclosporin A, betamethasone 17\u2010valerate, dexamethasone and hydrocortisone on cytokine production and T cell proliferation induced in human peripheral blood mononuclear cells","volume":"121","author":"Winiski A","year":"2003","journal-title":"J Invest Dermatol"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2249.2002.01962.x"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1357-2725(03)00208-5"},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/s004030050343"},{"key":"e_1_2_8_21_2","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2001.116865"},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.3109\/9780203908877-15"},{"key":"e_1_2_8_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1471-4906(02)02281-0"},{"key":"e_1_2_8_24_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2249.2003.02225.x"},{"key":"e_1_2_8_25_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.2003.12550_5.x"},{"key":"e_1_2_8_26_2","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2001.112600"},{"key":"e_1_2_8_27_2","first-page":"553","article-title":"In vitro treatment of dendritic cells with tacrolimus: impaired T\u2010cell activation and IP\u201010 expression","volume":"19","author":"Tiefenthaler M","year":"2004","journal-title":"Transplantation"},{"key":"e_1_2_8_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2004.03.021"},{"key":"e_1_2_8_29_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2003.05559.x"},{"issue":"3","key":"e_1_2_8_30_2","first-page":"353","article-title":"Pimecrolimus, tacrolimus, cyclosporine A and corticosteroids: effects on human T cell activation in vitro","volume":"17","author":"Winiski A","year":"2003","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"e_1_2_8_31_2","first-page":"1243","article-title":"Pimecrolimus does not affect cytokine and chemokine secretion and adhesion molecule expression in primary human keratinocytes and dermal fibroblasts","volume":"121","author":"Wolff B","year":"2003","journal-title":"J Invest Dermatol"},{"key":"e_1_2_8_32_2","first-page":"173","article-title":"Side effects of potent topical corticosteroids","volume":"118","author":"Jackson R.","year":"1978","journal-title":"Can Med Assoc J"},{"key":"e_1_2_8_33_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-198800365-00005"},{"key":"e_1_2_8_34_2","first-page":"123","article-title":"Adverse effects of topical corticosteroid use","volume":"162","author":"Fisher D A.","year":"1995","journal-title":"West J Med"},{"key":"e_1_2_8_35_2","first-page":"148","article-title":"Cushing's syndrome caused by topical steroid therapy for psoriasis","volume":"60","author":"Abma E M","year":"2002","journal-title":"Neth J Med"},{"key":"e_1_2_8_36_2","doi-asserted-by":"publisher","DOI":"10.2165\/00128071-200203010-00005"},{"key":"e_1_2_8_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2003.07.013"},{"issue":"2","key":"e_1_2_8_38_2","first-page":"109","article-title":"Pimecrolimus (Elidel\u00ae, SDZ ASM 981) cream 1% blood levels are consistently low in children with extensive atopic dermatitis","volume":"15","author":"Harper J","year":"2001","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"e_1_2_8_39_2","doi-asserted-by":"publisher","DOI":"10.1136\/adc.88.11.969"},{"key":"e_1_2_8_40_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1986.tb06242.x"},{"key":"e_1_2_8_41_2","doi-asserted-by":"crossref","unstructured":"DraelosZ D TofteS HanifinJ ChonK.Systemic exposure of pimecrolimus cream 1% and tacrolimus ointment 0.1% in adult patients with moderate to severe atopic dermatitis. Poster presented at AAD Washington 6\u201311 February 2004.","DOI":"10.1016\/j.jaad.2003.10.019"},{"key":"e_1_2_8_42_2","doi-asserted-by":"publisher","DOI":"10.1111\/1523-1747.ep12456939"},{"key":"e_1_2_8_43_2","doi-asserted-by":"publisher","DOI":"10.1159\/000236320"},{"key":"e_1_2_8_44_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1997.tb03788.x"},{"key":"e_1_2_8_45_2","first-page":"1S701","article-title":"Pimecrolimus (SDZ ASM 981) cream equals tacrolimus (FK506) ointment in efficacy in porcine allergic contact dermatitis","volume":"129","author":"Meingassner J G","year":"2002","journal-title":"Ann Dermatol Venereol"},{"key":"e_1_2_8_46_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2001.04076.x"},{"key":"e_1_2_8_47_2","first-page":"532","article-title":"SDZ ASM 981 is highly effective in animal models of skin inflammation, but has only low activity in models indicating immunosuppressive potential, in contrast to cyclosporin A and FK 506","volume":"117","author":"Meingassner J G","year":"2001","journal-title":"J Invest Dermatol"},{"key":"e_1_2_8_48_2","doi-asserted-by":"publisher","DOI":"10.1053\/sder.2001.29066"},{"key":"e_1_2_8_49_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.2003.12331.x"},{"key":"e_1_2_8_50_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2000.03411.x"},{"key":"e_1_2_8_51_2","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1096\/fj.03-0658fje","article-title":"Cutaneous allergic contact dermatitis responses are diminished in mice deficient in neurokinin 1 receptors and augmented by neurokinin 2 receptor blockage","volume":"9","author":"Scholzen T E","year":"2004","journal-title":"FASEB J"},{"key":"e_1_2_8_52_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00105-003-0521-6"},{"issue":"1","key":"e_1_2_8_53_2","article-title":"Pimecrolimus induces neuropeptide release at early stages of topical application in vivo (conference abstract)","volume":"121","author":"Steinhoff M","journal-title":"J Invest Dermatol 2003"},{"key":"e_1_2_8_54_2","first-page":"1S330","article-title":"The ascomycin derivatives ASM 981 (Pimecrolimus) and ASD 732 inhibit neuroinflammation in cutaneous hypersensitivity","volume":"129","author":"Armstrong C","year":"2002","journal-title":"Ann Dermatol Venereol"},{"key":"e_1_2_8_55_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0022-202X.2004.22324.x"},{"key":"e_1_2_8_56_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.toxlet.2003.12.027"},{"key":"e_1_2_8_57_2","first-page":"1S704","article-title":"Pimecrolimus (SDZ ASM 981) has high affinity for the skin \u2013 a tissue distribution study in rats in comparison with tacrolimus (FK 506)","volume":"129","author":"Schweitzer A","year":"2002","journal-title":"Ann Dermatol Venereol"},{"key":"e_1_2_8_58_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(20)80520-1"},{"key":"e_1_2_8_59_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(02)00699-2"},{"key":"e_1_2_8_60_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.273.20.12378"},{"key":"e_1_2_8_61_2","doi-asserted-by":"publisher","DOI":"10.1093\/embo-reports\/kvd090"},{"issue":"1","key":"e_1_2_8_62_2","first-page":"1192","article-title":"Pimecrolimus and tacrolimus differentially affect genes related to skin inflammation in rats","volume":"121","author":"Kehren J","year":"2003","journal-title":"J Invest Dermatol"},{"key":"e_1_2_8_63_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.110.1.e2"},{"key":"e_1_2_8_64_2","doi-asserted-by":"publisher","DOI":"10.1067\/mpd.2003.65"},{"key":"e_1_2_8_65_2","unstructured":"FDA\/Center for Drug Evaluation and Research.Elidel (pimecrolimus) cream. [Retrieved fromhttp:\/\/www.fda.gov\/cder\/foi\/nda\/2001\/21\u2010302]."},{"key":"e_1_2_8_66_2","first-page":"1072A","article-title":"Calcineurin inhibitors and skin cancer","volume":"121","author":"Tran C","year":"2003","journal-title":"J Invest Dermatol"},{"key":"e_1_2_8_67_2","first-page":"A119","article-title":"Pimecrolimus and tacrolimus show comparable potencies to inhibit the proliferation and cytokine synthesis of allergen\u2010specific, atopic skin\u2010derived T cell clones in vitro","volume":"122","author":"Kalthoff F S","year":"2004","journal-title":"J Invest Dermatol"},{"key":"e_1_2_8_68_2","first-page":"A40","article-title":"In vitro penetration\/permeation of pimecrolimus and tacrolimus from their marketed formulations (Elidel and Protopic)","volume":"122","author":"Billich A","year":"2004","journal-title":"J Invest Dermatol"},{"key":"e_1_2_8_69_2","first-page":"1S701","article-title":"Pimecrolimus (SDZ ASM 981) and tacrolimus (FK 506) target skin and peripheral lymphoid organs differently in mice and rats","volume":"129","author":"Meingassner J G","year":"2002","journal-title":"Ann Dermatol Venereol"}],"container-title":["Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.0906-6705.2004.00269.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.0906-6705.2004.00269.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T04:26:25Z","timestamp":1696998385000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.0906-6705.2004.00269.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,11,18]]},"references-count":68,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2004,12]]}},"alternative-id":["10.1111\/j.0906-6705.2004.00269.x"],"URL":"https:\/\/doi.org\/10.1111\/j.0906-6705.2004.00269.x","archive":["Portico"],"relation":{},"ISSN":["0906-6705","1600-0625"],"issn-type":[{"value":"0906-6705","type":"print"},{"value":"1600-0625","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,11,18]]}}}